



Sodium valproate Solution for Injection

New IIP-EU-Development Line

Therapeutic indication: Epilepsy



Solution for Injection


1 ml of the solution contains:
100 mg Sodium valproate

1 ampoule contains 4 ml.



We expressly point out that these dossiers or marketing authorisations cannot be used in countries where corresponding medicinal products or the application of such products are protected by patent.

Prescriptions of Antiepileptics (German Market)



Source: Schwabe, Paffrath Arzneiverordnungsreport

Product Advantages: High Quality IIP-EU-Development Line

- Dossier scheduled for November 2013 for solution for injection 100 mg/ml
- **cGMP compliant, European API manufacturer**
- API with CEP incorporated in the dossier
- **cGMP compliant, European contract manufacturer with high manufacturing capacities for sale peaks**
- Same viscosity and pH as originator
- Compatible to standard infusion liquids (e.g. ringer, glucose, NaCl solutions)
- Competitive prices
- Stable product in inert glass ampoules
- Easy to open standard „one point cut“ ampoules
- IIP-Dossiers also available for oral solution 100 mg/ml, gastro-resistant tablets 150, 300 and 600 mg and Sodium Valproate / Valproic Acid prolonged-release film-coated tablets 200, 300 and 500 mg
- Oral Solution, solution for injection, gastro-resistant tablets and sodium valproate/valproic acid prolonged-release film-coated tablets ⇒ Complete package for Sodium Valproate /Valproic acid available
- Samples and exposé with scientific data available upon request



IIP – Institut für industrielle Pharmazie Forschungs- und Entwicklungsgesellschaft mbH

Management
Benzstraße 2a
63741 Aschaffenburg, Germany
Tel.: 00 49 - (0) 60 21-5 85 93 - 0
Fax: 00 49 - (0) 60 21-5 85 93 - 28
E-Mail: management@iip.de
www.iip.de

Regulatory affairs – Technical department
Benzstraße 2a
63741 Aschaffenburg, Germany
Tel.: 00 49 - (0) 60 21-5 85 93 - 0
Fax: 00 49 - (0) 60 21-5 85 93 - 28
E-Mail: regaffairs@iip.de
www.iip.de